All News

Does infusion timing matter in TNBC? Early-day pembrolizumab may boost pCR and cut recurrences, prompting new scheduling questions.

Clonal blood mutations common in breast cancer may sharply raise heart failure risk after anthracyclines, urging better screening and personalized cardio-oncology care.

Data from the MAXILUS study affirm the importance of early treatment initiation among those with lower-risk myelodysplastic syndrome.

High rates of MRD negativity were observed with a combination of carfilzomib, lenalidomide, daratumumab, and dexamethasone in the ASCENT trial.

There was no clear prognostic impact of age, comorbidities, complex living skills, or basic self-care tasks on PFS for diffuse large B-cell lymphoma.

Findings from the phase 3 CAPItello-281 trial supported the regulatory decision for capivasertib among this PTEN-deficient HSPC group.

Based on data from the phase 3 LITESPARK-022 trial, the FDA has approved adjuvant belzutifan/pembrolizumab for patients with clear cell RCC.

Investigators observed no new safety signals with lurbinectedin alone or in combination with irinotecan in the phase 3 LAGOON trial.

Atezolizumab plus chemotherapy reduced the risk of disease recurrence or death by 50% compared with chemotherapy alone in this patient population.

A phase 1b/2 trial of azacitidine, venetoclax, and ivosidenib showed composite complete remissions and MRD negativity in newly diagnosed IDH1-mutated AML.

Findings from the ASC4FIRST trial show that asciminib is meeting high expectations as a frontline therapy in chronic myeloid leukemia in chronic phase.

Explore how ADCs reshape breast cancer care, with practical sequencing strategies across subtypes and guideline-based toxicity management for ILD, neutropenia, and GI effects.

Real-world data show most first-line mTNBC patients are immunotherapy-ineligible, use chemotherapy, and face poorer survival, underscoring major unmet treatment needs.

The addition of epcoritamab to lenalidomide and rituximab showed improved efficacy and manageable safety in relapsed/refractory follicular lymphoma.

Data from the CASSIOPEIA trial showed that more than half of patients with high-risk disease achieved 5-year disease-free survival with tisagenlecleucel.

Adverse drug reactions occurred in 1 patient treated with VT-EBV-N, although no grade 3 or higher events emerged.

Phase 3 results support anbenitamab plus albumin-bound docetaxel as a new treatment option in HER2-positive breast cancer across disease stages.

Experts discuss how updated findings from the TALAPRO-3 and PROTEUS trials may impact the prostate cancer paradigm.

T-DXd demonstrated a real-world overall response rate of 56.3%, median rwPFS of 7.4 months, and 12-month OS of 62% in patients with HER2-low metastatic breast cancer treated across US community oncology settings.

In a real-world cohort of 300 patients with HER2-low metastatic breast cancer, T-DXd demonstrated a safety profile consistent with DESTINY-Breast04 in community oncology settings, with ILD/pneumonitis in 10% and toxicity-related discontinuation in 15%.

Updated data from the ASC4FIRST trial affirm asciminib as the treatment of choice for many patients with chronic myeloid leukemia in chronic phase.

A recommendation from the external data monitoring committee led to the discontinuation of the phase 3 KEYNOTE D46/EVOKE-03 study.

Karen Reckamp, MD, MS, analyzed the shifting funding models in academic oncology and the necessity of philanthropy to support clinical trial infrastructure.

Zovegalisib plus fulvestrant demonstrated an objective response rate of 38.7% and a median progression-free survival of 10.3 months in PIK3CA-mutant HR+/HER2– advanced breast cancer in the ReDiscover trial.

ctDNA-based next-generation sequencing in 236 patients with advanced breast cancer revealed frequent PIK3CA, TP53, and ESR1 mutations, highlighting key mechanisms of endocrine resistance with implications for targeted therapy selection.

The clearance enables the developers to include China-based centers in an ongoing phase 1a/1b trial evaluating the agent in late-stage solid tumors.

Daraxonrasib plus vopimetostat demonstrated a favorable RAS-associated safety profile in patients with MTAP-deleted, pretreated metastatic pancreatic ductal adenocarcinoma.

Sarah Weiss, MD, highlights pivotal updates in uveal melanoma, intratumoral neoadjuvant therapy, and Merkel cell carcinoma from the 2026 ASCO Annual Meeting.

Higher ACE counts were significantly associated with greater symptom burden during anti-estrogen therapy in patients with stage I to IV breast cancer in the Appalachian region of Tennessee.

Dato-DXd plus durvalumab demonstrated robust antitumor activity as first-line treatment for advanced/metastatic triple-negative breast cancer in the phase 1b/2 BEGONIA study, with manageable safety.